LENZ Therapeutics (LENZ) to Release Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) will likely be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of ($1.0505) per share and revenue of $2.3770 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:00 PM ET.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.22). The business had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.76 million. LENZ Therapeutics had a negative net margin of 519.30% and a negative return on equity of 46.82%. On average, analysts expect LENZ Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

LENZ Therapeutics Price Performance

Shares of NASDAQ:LENZ opened at $5.16 on Wednesday. LENZ Therapeutics has a 1-year low of $4.68 and a 1-year high of $50.40. The stock has a market cap of $161.77 million, a P/E ratio of -1.43 and a beta of 0.62. The firm has a fifty day moving average price of $6.40 and a 200 day moving average price of $10.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Zacks Research cut shares of LENZ Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Weiss Ratings upgraded LENZ Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 17th. Bank of America reduced their price objective on LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Citigroup decreased their price objective on LENZ Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Finally, Piper Sandler downgraded LENZ Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $39.00 to $12.00 in a research note on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $29.80.

Institutional Trading of LENZ Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new position in LENZ Therapeutics during the third quarter worth about $27,000. Osaic Holdings Inc. increased its holdings in LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after buying an additional 1,116 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after buying an additional 477 shares in the last quarter. State of Wyoming acquired a new stake in shares of LENZ Therapeutics during the 4th quarter valued at approximately $30,000. Finally, BNP Paribas Financial Markets lifted its position in shares of LENZ Therapeutics by 93.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after acquiring an additional 944 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.